Topical Polypeptide Burn Treatment for NF-kB Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for burns and deep wounds, such as those using recombinant human growth factors, have limitations in promoting wound healing and can lead to inconsistent NF-kB expression, inflammation, and scar hyperplasia, with potential side effects.
Innovation Solution
A 15-amino acid polypeptide (SEQ ID No: 1) is used in topical formulations at ≥0.01% wt. to inhibit NF-kB activity, reducing inflammation and promoting skin regeneration, with formulations including liquid, ointment, and gel medicaments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If recombinant human growth factor gel (rh-EGF, rh-bFGF) is used to treat burns, then wound healing is promoted, but NF-kB expression becomes inconsistent and scar hyperplasia occurs
Solution Approach 1:
The treatment approach is segmented into two distinct functions: first, inhibiting NF-kB activity to prevent inflammation and scar formation; second, promoting wound healing through epithelial cell proliferation. This segmentation allows each function to be optimized independently without the conflicting side effects of combined growth factor therapy.
Solution Approach 2:
The patent introduces a peptidomimetic compound as an intermediary substance that specifically targets and inhibits NF-kB activity. This intermediary acts as a mediator between the harmful inflammatory response and the healing process, blocking the harmful signaling pathway while allowing beneficial healing mechanisms to proceed.
2Reliability
If growth factor gel is applied to deep wounds, then epithelial regeneration is promoted, but inflammation and inconsistent NF-kB expression occur
Solution Approach 1:
The patent converts the harmful role of NF-kB (which causes inflammation and inconsistent healing) into a beneficial approach by specifically inhibiting it. By targeting NF-kB inhibition, the treatment harnesses the knowledge of NF-kB's harmful effects and transforms it into a therapeutic mechanism that prevents inflammation while promoting consistent epithelial regeneration.
Solution Approach 2:
The patent changes the key parameter from promoting growth factor activity to inhibiting NF-kB activity. This parameter change fundamentally shifts the therapeutic mechanism from one that causes inconsistent NF-kB expression to one that consistently suppresses harmful NF-kB signaling while maintaining reliable wound healing outcomes.
3Productivity
If conventional burn treatments are used, then wound repair is achieved, but toxic side effects occur
Solution Approach 1:
The patent employs a peptidomimetic compound that acts as a temporary, localized treatment agent. This compound provides its therapeutic effect during the critical wound healing phase and then degrades, avoiding long-term toxic accumulation. The short-lived nature of the active compound ensures high efficacy during treatment while minimizing persistent side effects.
Data Source
Figure 1
Figure 2~3
Figure 4~5
AI summary
The invention discloses an application of polypeptide in preparation of skin damage treatment drug. The drug containing the polypeptide of the invention has good therapeutic effect on animal burn and scald models and trauma models, and has small toxic and side effects. It is an innovative drug with good development prospects, effective, safe and low toxicity, and controllable quality in the treatment of burn and scald.